Selected Practices:
Insight
AI in Clinical Trials: New Frontiers
The clinical trial landscape is changing, driven by artificial intelligence technologies that redefine what’s possible in therapeutic development. This revolution extends far beyond simple efficiency gains — AI fundamentally alters how trials are designed, conducted, monitored, and evaluated. Organizations that understand these shifts gain strategic advantages in speed-to-market, research quality, and patient-centricity.
Four transformational themes reshape clinical development and operations in 2025: the shift from sequential to parallel development processes, the democratization of clinical research, the convergence of clinical and real-world evidence, and the evolution from reactive to predictive trial management. Through these lenses, we can examine how AI in clinical trials creates interconnected capabilities that collectively represent a paradigm shift in how medical advances reach patients.
The Shift from Sequential to Parallel Clinical Development
Traditionally, clinical development operates as a linear, phase-gated process with distinct separations between discovery, preclinical testing, and the various clinical phases. AI dismantles these divisions, enabling simultaneous processes and continuous learning that accelerate timelines while improving decision quality.
Optimizing Trial Design Through Simulation
Protocol design evolves from an art to a data-driven science. AI-powered predictive analytics now evaluate thousands of variables to optimize study parameters before a single patient is enrolled. Sanofi exemplifies this approach through its implementation of digital twins — virtual patient simulations that allow researchers to test protocol designs in silico.
These digital twins exist at multiple levels: patient-level simulations model individual responses to treatments, cohort-level twins represent population characteristics, and operational trial-level twins simulate entire study execution. Each serves distinct purposes, from predicting individual outcomes to optimizing site selection and resource allocation.
One particularly promising application is supporting external control arms to reduce sample sizes needed in early-phase trials. By accurately modeling disease progression and treatment responses based on historical data, these simulations enable smaller, more focused studies while maintaining scientific validity. These AI simulations identify potential issues in study design, significantly reducing the risk of mid-trial amendments that typically delay timelines and increase costs.
Streamlining Patient-Trial Matching
The sequential approach to trial design followed by separate recruitment efforts is giving way to parallel, integrated processes. The NIH has made significant strides with tools like “TrialGPT,” which streamlines the process of matching patients with appropriate clinical trials while protocols are still being refined. Companies like Power are also advancing this field with sophisticated matching algorithms that consider numerous patient characteristics and trial requirements simultaneously.
This AI-driven approach analyzes complex eligibility criteria across thousands of active studies, matching patient profiles to relevant trials in seconds rather than weeks. These tools transform recruitment from a bottleneck to a strategic advantage, particularly for therapeutic areas with historically challenging enrollment.
The parallel processing capability created by AI allows for continuous refinement where protocol adjustments can be made based on real-time recruitment insights, creating a feedback loop impossible in traditional linear development models.
Democratization of Clinical Research
Perhaps the most profound impact of AI in clinical trials is its ability to democratize participation — extending research beyond academic medical centers and making trials accessible to broader, more diverse patient populations. This shift addresses longstanding ethical concerns while producing more generalizable results.
Enhancing Patient Diversity Through AI-Powered Recruitment Screening
AI algorithms scan electronic health records, analyze social media engagement, and evaluate community demographics to identify suitable candidates from underrepresented populations. Platforms like Inato specifically focus on connecting pharmaceutical sponsors with research sites that serve diverse patient populations, using AI to pre-screen patient populations and optimize matches.
These technologies enable more diverse patient enrollment by identifying potential participants who would typically remain invisible to traditional recruitment methods. The impact extends beyond regulatory compliance to generate more clinically relevant evidence about how therapies perform across different genetic backgrounds and comorbidity profiles.
Expanded Access Through AI-Enabled Hybrid Trials
While fully remote trials remain rare, hybrid approaches that combine traditional site visits with remote elements show promise. According to PMC publications, these technologies enhance real-time data collection while reducing both trial size and duration.
Patients benefit from reduced site visit frequency as AI algorithms analyze continuous data streams from wearable devices, flagging abnormalities and ensuring protocol compliance between in-person assessments. While this approach has not eliminated geographic barriers to participation as initially hoped, it has reduced patient burden and improved data collection quality.
These hybrid approaches represent an important step toward greater inclusivity, even as the industry continues working toward more comprehensive solutions for patients in truly remote locations.
Patient-Centric Trial Design
AI in clinical trials transforms how patient perspectives are incorporated. Rather than focusing solely on biomedical markers, AI tools analyze patient forums and social media to identify endpoints that truly matter to patients. AI-enabled interfaces simplify participation while providing personalized education about the trial process, collecting continuous feedback to help researchers adapt to participant concerns and reduce dropout rates.
Virtual patient advisory boards facilitated by AI natural language processing become standard practice, allowing diverse patient input from the earliest protocol development stages. This collaborative approach ensures trials address patient priorities regarding visit frequency, procedure burden, and meaningful outcomes — creating studies that patients want to join and complete.
This democratization creates a virtuous cycle: more diverse participation leads to more representative data, which in turn produces more generalizable results that benefit broader patient populations and strengthen regulatory submissions.
The Convergence of Clinical and Real-World Evidence
The sharp distinction between controlled clinical trials and real-world observation is disappearing. AI technologies create a continuum of evidence generation where insights flow seamlessly between traditional trials and real-world use, fundamentally altering how pharmaceutical companies establish efficacy and safety.
AI for Synthetic Control Arms
Applied Clinical Trials reports that AI enables new approached to control arms through analysis of real-world data (RWD). Rather than completely replacing traditional placebo groups, these synthetic or external control arms allow for reduced sample sizes while maintaining scientific validity. This approach addresses ethical concerns about placebo use while improving trial efficiency. AI algorithms analyze historical patient data to create virtual control groups, allowing more study participants to receive active treatments while still generating credible comparative evidence.
When implemented effectively, synthetic control arms can reduce trial costs while addressing the ethical dilemma of withholding potentially beneficial treatments from control group participants. Similar to digital twins, synthetic control arms exemplify how AI facilitates the harmonization of clinical rigor with real-world evidence generation.
Continuous Post-Market Surveillance
The artificial separation between pre-approval research and post-market monitoring continues to dissolve. AI transforms post-approval surveillance from a reactive to a proactive function integrated with the broader evidence generation strategy. Machine learning algorithms continuously analyze real-world data from multiple sources to detect potential safety signals earlier than traditional methods allow. This enhanced surveillance capability not only improves patient safety but also provides valuable insights that inform ongoing clinical development.
Now, real-world effectiveness data supports both regulatory requirements and commercial objectives, creating a seamless connection between clinical research and market access strategies that was previously unattainable without AI-powered analytics.
Predictive vs. Reactive Trial Management
Traditionally, pharmaceutical companies manage clinical trials reactively — issues are addressed as they arise, or needing “rescue,” often after significant time and resources have been invested. AI in clinical trials shifts this paradigm toward predictive management where potential problems are identified and mitigated before they impact trial integrity or patient safety.
AI in Risk-Based Monitoring
The traditional approach to site monitoring has given way to risk-based strategies powered by AI. Machine learning algorithms continuously assess data quality, patient safety indicators, and protocol compliance, triggering alerts when patterns suggest potential issues — often before human monitors would recognize them. This proactive stance significantly enhances data accuracy and patient safety while reducing the resource burden of comprehensive on-site monitoring.
Performance-based KPIs now track metrics on enrollment, data quality, and investigator performance. When combined with AI-driven risk assessment, these benchmarks create a powerful framework for optimizing trial oversight, directing resources to the highest-risk sites and activities while maintaining confidence in data from lower-risk areas.
Real-Time Data Integration and Analysis
The proliferation of data sources in modern clinical trials — from electronic case report forms to wearables, sensors, and remote monitoring devices — creates new challenges and opportunities in trial management. AI serves as the crucial link, processing continuous data streams from these diverse sources to provide real-time insights. According to Informatica, AI in clinical trials revolutionizes data pipelines in R&D by integrating real-time trial data from multiple sources and improving analysis capabilities.
This unified approach to data integration ensures that information from remote monitoring technologies (discussed earlier) can be seamlessly incorporated into the broader trial dataset, enabling comprehensive analysis across all patient interactions regardless of collection method. These capabilities enable clinical teams to make data-informed decisions faster, shifting the focus from managing problems to preventing them.
Regulatory Adaptation to AI-Driven Clinical Trials
As these four themes reshape the clinical trial landscape, regulatory frameworks evolve in response. The FDA is actively evaluating AI in clinical trials, setting guidelines for its use in patient monitoring and data analysis. This evolving landscape requires careful navigation, particularly regarding data integrity and privacy concerns.
Reuters reports that the Department of Justice is establishing new compliance guidelines focused specifically on AI applications in healthcare, with particular attention to data integrity and governance. These developments require organizations to implement robust validation protocols for AI systems used in regulatory-critical functions, ensuring that innovation advances within appropriate compliance frameworks.
Simultaneously, regulatory agencies face their own capacity challenges as AI accelerates trial completion and increases submission volumes. This drives regulatory authorities to explore AI-powered review tools to manage workload while maintaining thorough scientific assessment. The result may be a regulatory ecosystem where AI tools on both sides — sponsor and regulator — must be designed to interact effectively.
Data integrity and standardization have become critical success factors for AI implementation. Ensuring interoperability across diverse clinical trial data sources while maintaining regulatory compliance presents both technical and operational challenges. Organizations must establish rigorous validation protocols for AI systems, particularly those supporting regulatory submissions or patient safety monitoring.
The Future: AI-Driven Personalization in Clinical Research
Looking ahead, these themes converge in the personalization of clinical research. AI enables tailored research approaches based on individual patient characteristics, potentially revolutionizing treatment for rare diseases and complex conditions. This precision approach improves treatment efficacy while reducing sample size requirements, making previously unfeasible studies viable.
While AI promises tremendous benefits, significant challenges remain. Trust emerges as perhaps the most critical barrier — trust in AI data quality, process transparency, and predictive accuracy. As current AI systems struggle with hallucinations and fabricated data, rigorous validation frameworks become essential for clinical applications where patient safety is at stake.
Related: How AI is Reshaping the Future of Life Sciences
As these technologies mature, the balance between innovation and ethical considerations will remain paramount. The key to successful implementation lies not in technology alone, but in thoughtful application that enhances — rather than replaces — human judgment in the pursuit of better patient outcomes.
Empowering the Clinical Workforce for AI-Driven Innovation
While addressing technical challenges is crucial, the human dimension of AI adoption determines its ultimate impact. This requires both continuous workforce upskilling and thoughtful attention to ethical questions around algorithm bias and patient privacy.
Creating a bottom-up innovation culture represents a strategic imperative that complements technological implementation. The teams closest to clinical operations — data managers, clinical research associates, biostatisticians, and site coordinators — often identify the most valuable AI applications when empowered with both knowledge and autonomy.
The life sciences industry is still in the early stages of utilizing AI in clinical trials. When teams understand both AI’s capabilities and limitations, they discover innovative applications that transcend basic efficiency gains. This deeper knowledge empowers them to fundamentally reimagine trial design, transform patient engagement approaches, and develop novel operational strategies that would otherwise remain undiscovered.
Harnessing this potential, a human-centered approach to AI integration transforms the adoption curve from implementation to co-creation. When clinical teams actively participate in developing AI use cases rather than merely receiving them, the resulting solutions address real-world challenges while gaining broader organizational acceptance. This collaborative model creates a virtuous cycle where practical insights inform technology development, which then enables more sophisticated applications.
The most successful organizations in this space do not merely invest in AI tools — they invest in creating environments where their workforce can reimagine clinical processes with AI as a collaborator rather than just an efficiency tool.
Conclusion: Strategic Imperatives for Clinical Innovation
The integration of AI into clinical development and operations represents a fundamental shift in how pharmaceutical companies develop, test, and monitor treatments. From protocol design to post-market surveillance, AI enhances every aspect of the development lifecycle, improving efficiency, data quality, and patient experience while breaking down traditional gates between development phases, research settings, evidence types, and management approaches.
As the clinical ecosystem continues to evolve, the balance between technological innovation and human expertise will remain critical. Organizations that successfully navigate this transformation will require AI implementation skills and strategic vision to reimagine clinical processes for the digital age. Acquis is positioned to help pharmaceutical companies develop comprehensive strategies that align with the evolving landscape of clinical development and operations and transform clinical trials from traditional, site-based activities to AI-powered, patient-centric experiences that accelerate therapeutic development and enhance data quality and research efficiency.